MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $166.31 million. The enterprise value is $63.58 million.
Important Dates
The next confirmed earnings date is Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 106.61 million shares outstanding. The number of shares has increased by 1.72% in one year.
| Current Share Class | 106.61M |
| Shares Outstanding | 106.61M |
| Shares Change (YoY) | +1.72% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 1.41% |
| Owned by Institutions (%) | 67.43% |
| Float | 96.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.82 |
| Forward PS | 4.60 |
| PB Ratio | 0.91 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.39, with a Debt / Equity ratio of 0.10.
| Current Ratio | 12.39 |
| Quick Ratio | 11.45 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -21.73% and return on invested capital (ROIC) is -14.89%.
| Return on Equity (ROE) | -21.73% |
| Return on Assets (ROA) | -14.18% |
| Return on Invested Capital (ROIC) | -14.89% |
| Return on Capital Employed (ROCE) | -25.69% |
| Revenue Per Employee | $313,632 |
| Profits Per Employee | -$392,737 |
| Employee Count | 114 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.76 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.33% in the last 52 weeks. The beta is 0.27, so MaxCyte's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -57.33% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 2.55 |
| Relative Strength Index (RSI) | 50.05 |
| Average Volume (20 Days) | 635,120 |
Short Selling Information
The latest short interest is 3.43 million, so 3.22% of the outstanding shares have been sold short.
| Short Interest | 3.43M |
| Short Previous Month | 3.24M |
| Short % of Shares Out | 3.22% |
| Short % of Float | 3.57% |
| Short Ratio (days to cover) | 4.24 |
Income Statement
In the last 12 months, MaxCyte had revenue of $35.75 million and -$44.77 million in losses. Loss per share was -$0.42.
| Revenue | 35.75M |
| Gross Profit | 28.53M |
| Operating Income | -53.48M |
| Pretax Income | -44.77M |
| Net Income | -44.77M |
| EBITDA | -49.16M |
| EBIT | -53.48M |
| Loss Per Share | -$0.42 |
Full Income StatementBalance Sheet
The company has $126.56 million in cash and $18.51 million in debt, giving a net cash position of $108.06 million or $1.01 per share.
| Cash & Cash Equivalents | 126.56M |
| Total Debt | 18.51M |
| Net Cash | 108.06M |
| Net Cash Per Share | $1.01 |
| Equity (Book Value) | 190.72M |
| Book Value Per Share | 1.79 |
| Working Capital | 131.66M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$36.48 million and capital expenditures -$1.79 million, giving a free cash flow of -$38.27 million.
| Operating Cash Flow | -36.48M |
| Capital Expenditures | -1.79M |
| Free Cash Flow | -38.27M |
| FCF Per Share | -$0.36 |
Full Cash Flow StatementMargins
Gross margin is 79.79%, with operating and profit margins of -149.57% and -125.22%.
| Gross Margin | 79.79% |
| Operating Margin | -149.57% |
| Pretax Margin | -125.22% |
| Profit Margin | -125.22% |
| EBITDA Margin | -137.49% |
| EBIT Margin | -149.57% |
| FCF Margin | n/a |
Dividends & Yields
MaxCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.72% |
| Shareholder Yield | -1.72% |
| Earnings Yield | -26.09% |
| FCF Yield | -22.29% |
Analyst Forecast
The average price target for MaxCyte is $7.50, which is 380.77% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.50 |
| Price Target Difference | 380.77% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 28.61% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaxCyte has an Altman Z-Score of 6.39 and a Piotroski F-Score of 1.
| Altman Z-Score | 6.39 |
| Piotroski F-Score | 1 |
